If the answer is 'Yes', you might be a candidate to participate in a clinical study on the treatment of Critical Limb Ischemia (CLI). In this study named ‘Salamander’, a novel cell therapy is tested.
The study intends to evaluate the effects of a new cell therapy that is prepared using your own bone marrow. This study involves an experimental product called REX-001 and a placebo. There is a 33% probability that you will receive placebo. When all study patients are followed up for 12 months, patients assigned to the placebo group will be offered to be treated with the experimental product.
REX-001 consists of cells present in a patient’s own bone marrow. REX-001 is expected to improve the quality of existing vessels and stimulate the formation of new blood vessels. As a result, the blood flow in the patient’s leg could be significantly improved. The pain at rest that patients may experience could be resolved and wounds on toes or feet could heal.